Press Releases

Novan to Present Successful Clinical Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris

January 15, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that data from a clinical study to assess the safety and pharmacokinetics of SB204 Gel in patients with moderate to severe acne was accepted for presentation at the World Congress of Dermatology to be held in Vancouver on June 8-15, 2015.  This global event is held once every five years and is organized by the International League of Dermatological Societies (ILDS).

Full Story